Pub Date : 2017-02-27DOI: 10.12974/2312-5411.2017.04.4
F. Jenhani, Z. Regaya, L. Berraies, F. Mellouli
AIM: A regular monitoring of the immune reconstitution mainly based on the quantitative determination of lymphocyte T subpopulation. This is prospective analysis for 1 year in Tunisian children treated with allogenic intrafamilial bone marrow transplantation. Methods: We conducted a prospective analysis for 1 year follow up enrolling 25 children treated with allogenic intrafamilial bone marrow transplantation among them two cases of Peripheral hematopoietic transplantation and placental cord blood transplantation including: aplastic anemia (6 cases), hemoglobinopathies (12 cases), myelodysplastic syndrome (1 case), 2 cases of Acute lymphocytic leukemia, a case of congenital amegacarycytosis and 3 cases of primary immunodeficiency with lack of expression of major MHC class II. All subjects received different conditioning regimens according to the indication. Our study consisted of a regular monitoring of the immune reconstitution mainly based on the quantitative determination of lymphocyte T subpopulation. So, these tests were routinely requested to 1 month, 2 months, 3 months, 6 months, 9 months and 12 months post- bone marrow transplantation. Results: The average time of engraftment was 18 days corresponding to neutrophil recovery (12-24). For the T cell recovery, a rate of CD4 + T lymphocytes > 200/ mm3 was provided within an average of 2.5 months (1-7). The average time to obtain CD8+ T lymphocytes >200 /mm3 was 2 months (1-5). The humoral immune reconstitution was made within an average of 2 months (1-4). A ratio of CD4+ / CD8+ T lymphocytes (>1) was obtained within 10 months and a half (1-24). Univaried analysis showed a significant correlation between the bone marrow sex matched and the faster reorganization of CD8 + T cells (p = 0.042). Moreover, a quantity of CD34 +> 6x 106/ kg was significantly associated with the recapture of a formula lymphocyte T CD4+ / CD8+ (> 1) (p=0.03). Conclusion: The immune recovery post bone marrow transplantation in children began with myeloid lineage then lymphoid B then lymphoid T. The inversion of the ratio CD4 +/CD8+ T lymphocytes, seemed to be influenced on the one hand by the high content of CD34 + cells in the graft as well as the type of conditioning on the other hand by the CMV infection since it accelerates significantly CD8+ T lymphocyte reconstitution.
{"title":"Immune and Hematological Reconstitution after Allogenic Bone Marrow Transplantation in Tunisian Pediatric Recipients: Prospective Study and Tunisian Experience Report","authors":"F. Jenhani, Z. Regaya, L. Berraies, F. Mellouli","doi":"10.12974/2312-5411.2017.04.4","DOIUrl":"https://doi.org/10.12974/2312-5411.2017.04.4","url":null,"abstract":"AIM: A regular monitoring of the immune reconstitution mainly based on the quantitative determination of lymphocyte T subpopulation. This is prospective analysis for 1 year in Tunisian children treated with allogenic intrafamilial bone marrow transplantation.\u0000Methods: We conducted a prospective analysis for 1 year follow up enrolling 25 children treated with allogenic intrafamilial bone marrow transplantation among them two cases of Peripheral hematopoietic transplantation and placental cord blood transplantation including: aplastic anemia (6 cases), hemoglobinopathies (12 cases), myelodysplastic syndrome (1 case), 2 cases of Acute lymphocytic leukemia, a case of congenital amegacarycytosis and 3 cases of primary immunodeficiency with lack of expression of major MHC class II. All subjects received different conditioning regimens according to the indication. Our study consisted of a regular monitoring of the immune reconstitution mainly based on the quantitative determination of lymphocyte T subpopulation. So, these tests were routinely requested to 1 month, 2 months, 3 months, 6 months, 9 months and 12 months post- bone marrow transplantation.\u0000Results: The average time of engraftment was 18 days corresponding to neutrophil recovery (12-24). For the T cell recovery, a rate of CD4 + T lymphocytes > 200/ mm3 was provided within an average of 2.5 months (1-7). The average time to obtain CD8+ T lymphocytes >200 /mm3 was 2 months (1-5). The humoral immune reconstitution was made within an average of 2 months (1-4). A ratio of CD4+ / CD8+ T lymphocytes (>1) was obtained within 10 months and a half (1-24). Univaried analysis showed a significant correlation between the bone marrow sex matched and the faster reorganization of CD8 + T cells (p = 0.042). Moreover, a quantity of CD34 +> 6x 106/ kg was significantly associated with the recapture of a formula lymphocyte T CD4+ / CD8+ (> 1) (p=0.03).\u0000Conclusion: The immune recovery post bone marrow transplantation in children began with myeloid lineage then lymphoid B then lymphoid T. The inversion of the ratio CD4 +/CD8+ T lymphocytes, seemed to be influenced on the one hand by the high content of CD34 + cells in the graft as well as the type of conditioning on the other hand by the CMV infection since it accelerates significantly CD8+ T lymphocyte reconstitution. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46563098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-27DOI: 10.12974/2312-5411.2017.04.2
Maczy González, M. Arteaga-Vizcaíno, Ana Ruiz, Jesús Estévez, Jesus Quintero, M. Quintero, O. Briceño, R. Atencio, Ivis Marcano
PRP is an useful bioproduct to tisular regeneration. The aim of study was evaluate the concentration of growth factors: PDGFBB (platelet-derived growth factor), EGF(epidermal growth factor) and VEGF (vascular endothelial growth factor) present in the Platelet-rich plasma (PRP) in subjects treated with drugs which inhibit platelet aggregation as acetylsalicylic acid (ASA) and clopidogrel before and after administration. We determined by ELISA PDGFBB, EGF and VEGF levels in PRP, Platelet Poor Plasma (PPP), lysate and exudate from 32 healthy subjects before and 24 hours after ingesting acid Acetyl salicylic acid (ASA) and clopidogrel as a single dose. The PRP and PPP were obtained by the method of Anitua by single centrifugation method. To analyze the results of student test and Pearson correlation was applied, with statistical significance level of p < 0.05. PPP and exudate (Clopidogrel: p < 0.001), PRP (Clopidogrel: p < 0.01) statistically significant differences for PDGFBB in PPP (p < 0.01 AAS) were found, and for VEGF in lysate (ASA and Clopidogrel: p < 0.05). No significant difference was found for EGF. Only was no correlation between baseline values of EGF in the ASA group and the respective PRP platelet count (r = 0.726). The results show that the average basal values of the three growth factors measured were considered particularly high in the PRP and lysate, showing the significant decrease for PDGFBB after antiplatelet therapy, especially of Clopidogrel and a significant increase for the VEGF only for the lysate. Although the behavior of three different soluble mediators was different to antiplatelet agents, the observed changes support the conclusion that a single dose of these drugs not markedly affect the secretion and availability of the three growth factors measured in various platelet derived obtained.
{"title":"Growth Factors in the Platelet-Rich Plasma","authors":"Maczy González, M. Arteaga-Vizcaíno, Ana Ruiz, Jesús Estévez, Jesus Quintero, M. Quintero, O. Briceño, R. Atencio, Ivis Marcano","doi":"10.12974/2312-5411.2017.04.2","DOIUrl":"https://doi.org/10.12974/2312-5411.2017.04.2","url":null,"abstract":"PRP is an useful bioproduct to tisular regeneration. The aim of study was evaluate the concentration of growth factors: PDGFBB (platelet-derived growth factor), EGF(epidermal growth factor) and VEGF (vascular endothelial growth factor) present in the Platelet-rich plasma (PRP) in subjects treated with drugs which inhibit platelet aggregation as acetylsalicylic acid (ASA) and clopidogrel before and after administration. We determined by ELISA PDGFBB, EGF and VEGF levels in PRP, Platelet Poor Plasma (PPP), lysate and exudate from 32 healthy subjects before and 24 hours after ingesting acid Acetyl salicylic acid (ASA) and clopidogrel as a single dose. The PRP and PPP were obtained by the method of Anitua by single centrifugation method. To analyze the results of student test and Pearson correlation was applied, with statistical significance level of p < 0.05. PPP and exudate (Clopidogrel: p < 0.001), PRP (Clopidogrel: p < 0.01) statistically significant differences for PDGFBB in PPP (p < 0.01 AAS) were found, and for VEGF in lysate (ASA and Clopidogrel: p < 0.05). No significant difference was found for EGF. Only was no correlation between baseline values of EGF in the ASA group and the respective PRP platelet count (r = 0.726). The results show that the average basal values of the three growth factors measured were considered particularly high in the PRP and lysate, showing the significant decrease for PDGFBB after antiplatelet therapy, especially of Clopidogrel and a significant increase for the VEGF only for the lysate. Although the behavior of three different soluble mediators was different to antiplatelet agents, the observed changes support the conclusion that a single dose of these drugs not markedly affect the secretion and availability of the three growth factors measured in various platelet derived obtained. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44971150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-27DOI: 10.12974/2312-5411.2017.04.1
Rabeb M. Ghali, Sana Mahjoub, W. Bahia, Vera Chaieb, B. Achour, Faouzi Janhani, T. Mahjoub
Purpose: The prognostic of Acute leukemia is cell drug resistance dependent, which is principal cause of death. The bone marrow microenvironment is directly implicated as source of chemio resistance. Several researchers have studied in vivo and vitro the effect of the bioactive molecules such as the Thymoquinone (TQ) on cancers chemo resistant. The aim of this study is to compare the activities of Thymoquinone to Doxorubicin on presence and on absence of collagen type I, which is the major component of cell extra matrix (CEM). Methods: Cell line HL60 resistance against Doxorubicin and Thymoquinone was tested on presence and on absence Type I collagen at concentration 25, 50 and 100 µg /cm2 TQ and Dox cytototoxicities was evaluated with counting using KOVA Glasstic Slide and phase contrast microscopy. HL-60 cells were seeded at 10 cells/well for 24h in the presence or not of collagen and treated or not with 200nM of Dox or 10 µM of TQ. After incubation, apoptosis was determined using Annex V and Dead Cell Assay kit (Millipore) and Caspase 3/7 Assay kit (Millipore). Results: cell line HL60 proliferation is more resistance against Doxorubicin in presence Type I collagen than Thymoquinone. Conclusion: Collagen induce cell HL60 resistance against Doxorubicin, But not against Thymoquinone. Combination Thymoquinone, bioactive molecule, to Doxorubicin can decrease the drug resistance and improve leukemia prognostic.
{"title":"Resistance Studies, in vitro Model, of Myeloid Leukemia Cell Lines HL-60 Against Thymoquinone and Doxorubicin in the Presence of Type I Collagena","authors":"Rabeb M. Ghali, Sana Mahjoub, W. Bahia, Vera Chaieb, B. Achour, Faouzi Janhani, T. Mahjoub","doi":"10.12974/2312-5411.2017.04.1","DOIUrl":"https://doi.org/10.12974/2312-5411.2017.04.1","url":null,"abstract":"Purpose: The prognostic of Acute leukemia is cell drug resistance dependent, which is principal cause of death. The bone marrow microenvironment is directly implicated as source of chemio resistance. Several researchers have studied in vivo and vitro the effect of the bioactive molecules such as the Thymoquinone (TQ) on cancers chemo resistant. The aim of this study is to compare the activities of Thymoquinone to Doxorubicin on presence and on absence of collagen type I, which is the major component of cell extra matrix (CEM).\u0000Methods: Cell line HL60 resistance against Doxorubicin and Thymoquinone was tested on presence and on absence Type I collagen at concentration 25, 50 and 100 µg /cm2 TQ and Dox cytototoxicities was evaluated with counting using KOVA Glasstic Slide and phase contrast microscopy. HL-60 cells were seeded at 10 cells/well for 24h in the presence or not of collagen and treated or not with 200nM of Dox or 10 µM of TQ. After incubation, apoptosis was determined using Annex V and Dead Cell Assay kit (Millipore) and Caspase 3/7 Assay kit (Millipore).\u0000Results: cell line HL60 proliferation is more resistance against Doxorubicin in presence Type I collagen than Thymoquinone.\u0000Conclusion: Collagen induce cell HL60 resistance against Doxorubicin, But not against Thymoquinone. Combination Thymoquinone, bioactive molecule, to Doxorubicin can decrease the drug resistance and improve leukemia prognostic. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41813415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-27DOI: 10.12974/2312-5411.2017.04.3
K. Satué, J. C. Gardón, Á. Muñoz
Currently we can consider that, in addition to its role in hemostasis, platelets also participate in other important processes such as thrombosis, inflammation, tissue remodeling and the innate defense mechanisms. The hemostatic activity of platelets includes different events to stop bleeding. Within these functions we can mention the adhesion to the endothelium of the affected blood vessel, the activation, the aggregation, and the release of substances that initiate hemostatic events, and also the providing a phospholipid surface for activation of numerous coagulation factors. Similarly, platelets release multiple growth factors responsible for regulating the growth and division of endothelial cells and fibroblasts. In this way, among other things, angiogenesis and tissue regeneration are favored. Platelets also participate in inflammatory processes by the release of factors that initiate the inflammatory cascade and favor the chemotaxis of neutrophils, monocytes, macrophages, acute phase proteins and target cell signaling. Finally, platelets participate in the immune response by interacting with the complement system and immunoglobulins.
{"title":"Interpretation of Platelets in The Horse","authors":"K. Satué, J. C. Gardón, Á. Muñoz","doi":"10.12974/2312-5411.2017.04.3","DOIUrl":"https://doi.org/10.12974/2312-5411.2017.04.3","url":null,"abstract":"Currently we can consider that, in addition to its role in hemostasis, platelets also participate in other important processes such as thrombosis, inflammation, tissue remodeling and the innate defense mechanisms. The hemostatic activity of platelets includes different events to stop bleeding. Within these functions we can mention the adhesion to the endothelium of the affected blood vessel, the activation, the aggregation, and the release of substances that initiate hemostatic events, and also the providing a phospholipid surface for activation of numerous coagulation factors. Similarly, platelets release multiple growth factors responsible for regulating the growth and division of endothelial cells and fibroblasts. In this way, among other things, angiogenesis and tissue regeneration are favored. Platelets also participate in inflammatory processes by the release of factors that initiate the inflammatory cascade and favor the chemotaxis of neutrophils, monocytes, macrophages, acute phase proteins and target cell signaling. Finally, platelets participate in the immune response by interacting with the complement system and immunoglobulins. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43799977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-15DOI: 10.12974/2312-5411.2016.03.01.2
T. Parvu, C. Coclitu, O. Rusu, A. Ciobotaru, A. Mergeani, O. Bajenaru, F. Antochi
Recent studies showed that iron deficiency anemia was correlated with ischemic stroke in patients with carotid artery stenosis. It was also identified as the culprit of ischemic stroke in patients without any acknowledged risk factors for stroke. We presented a clinical case that highlights the importance of the management of anemia as etiologic factor of ischemic stroke, both as primary and secondary prevention.
{"title":"A Case of Ischemic Stroke in a Patient with Middle Cerebral Artery Stenosis and Iron Deficiency Anemia","authors":"T. Parvu, C. Coclitu, O. Rusu, A. Ciobotaru, A. Mergeani, O. Bajenaru, F. Antochi","doi":"10.12974/2312-5411.2016.03.01.2","DOIUrl":"https://doi.org/10.12974/2312-5411.2016.03.01.2","url":null,"abstract":"Recent studies showed that iron deficiency anemia was correlated with ischemic stroke in patients with carotid artery stenosis. It was also identified as the culprit of ischemic stroke in patients without any acknowledged risk factors for stroke. We presented a clinical case that highlights the importance of the management of anemia as etiologic factor of ischemic stroke, both as primary and secondary prevention. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66337644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-15DOI: 10.12974/2312-5411.2016.03.01.3
G. Mizejewski
Alpha-fetoprotein (AFP) is well known as a biomarker for certain cancers and fetal birth defects. However, AFP has long been overlooked as an indicator for the presence of anemia in various diseases of fetal, neonatal, and juvenile individuals. A survey and meta-analysis of the biomedical literature revealed that elevated levels of serum AFP may serve as a viable biomarker of moderate to severe anemia at various stages of ontogeny. Such conditions of anemia could include bone marrow failure, pancytopenia, macrocytosis, microcytosis, and aplastic anemia. Since many congenital diseases that result in anemia are progressive and lethal, the need for a biomarker that could predict and parallel the advancing anemic state in disease would be of utmost importance to the biomedical community.
{"title":"Is Alpha-Fetoprotein a New Biomarker for Fetal, Infant and Juvenile Anemia? A Commentary","authors":"G. Mizejewski","doi":"10.12974/2312-5411.2016.03.01.3","DOIUrl":"https://doi.org/10.12974/2312-5411.2016.03.01.3","url":null,"abstract":"Alpha-fetoprotein (AFP) is well known as a biomarker for certain cancers and fetal birth defects. However, AFP has long been overlooked as an indicator for the presence of anemia in various diseases of fetal, neonatal, and juvenile individuals. A survey and meta-analysis of the biomedical literature revealed that elevated levels of serum AFP may serve as a viable biomarker of moderate to severe anemia at various stages of ontogeny. Such conditions of anemia could include bone marrow failure, pancytopenia, macrocytosis, microcytosis, and aplastic anemia. Since many congenital diseases that result in anemia are progressive and lethal, the need for a biomarker that could predict and parallel the advancing anemic state in disease would be of utmost importance to the biomedical community. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66337809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-15DOI: 10.12974/2312-5411.2016.03.01.1
Y. Maeda, A. Okamoto, Shin-ichiro Kawaguchi, A. Konishi, Kenta Yamamoto, G. Eguchi, Terufumi Yamaguchi
Adult T-cell leukemia/lymphoma (ATL/ATLL) is an aggressive lymphoid disease caused by human T-cell leukemia virus type 1 (HTLV-1). It is reported that retinoid suppressed the proliferation of malignant cells including ATL cells. In this study, we showed the mechanism of retinoid action for ATL cells. We observed that NF-kB transcriptional activity as well as cell proliferation decreased in HTLV-1-positive T-cell lines by treatment with retinoid. Further, we observed that retinoid reduced HTLV-1 proviral DNA. Interestingly, retinoid significantly inhibited reverse transcriptase (RT) activity similar to azidothimidine (AZT) on HTLV-1-positive T-cell lines. Therefore, AZT was inhibitory of proviral DNA load but not NF-kB transcriptional activity on HTLV-I, however retinoid was inhibitory of both NF-?B and proviral DNA on HTLV-1. Furthermore, we showed cellular senescence in HTLV-I positive T-cell lines and in primary ATL cells obtained from acute ATL patients. The number of senescent cells significantly increased in the HTLV-I positive T-cell lines after treatment with retinoid, but not in the HTLV-I negative ones. These results indicated that retinoid could have three roles, as a NF-?B inhibitor, as a RT inhibitor and as a facilitating cellular senescence.
{"title":"Adult T-Cell Leukemia and Retinoid","authors":"Y. Maeda, A. Okamoto, Shin-ichiro Kawaguchi, A. Konishi, Kenta Yamamoto, G. Eguchi, Terufumi Yamaguchi","doi":"10.12974/2312-5411.2016.03.01.1","DOIUrl":"https://doi.org/10.12974/2312-5411.2016.03.01.1","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATL/ATLL) is an aggressive lymphoid disease caused by human T-cell leukemia virus type 1 (HTLV-1). It is reported that retinoid suppressed the proliferation of malignant cells including ATL cells. In this study, we showed the mechanism of retinoid action for ATL cells. We observed that NF-kB transcriptional activity as well as cell proliferation decreased in HTLV-1-positive T-cell lines by treatment with retinoid. Further, we observed that retinoid reduced HTLV-1 proviral DNA. Interestingly, retinoid significantly inhibited reverse transcriptase (RT) activity similar to azidothimidine (AZT) on HTLV-1-positive T-cell lines. Therefore, AZT was inhibitory of proviral DNA load but not NF-kB transcriptional activity on HTLV-I, however retinoid was inhibitory of both NF-?B and proviral DNA on HTLV-1. Furthermore, we showed cellular senescence in HTLV-I positive T-cell lines and in primary ATL cells obtained from acute ATL patients. The number of senescent cells significantly increased in the HTLV-I positive T-cell lines after treatment with retinoid, but not in the HTLV-I negative ones. These results indicated that retinoid could have three roles, as a NF-?B inhibitor, as a RT inhibitor and as a facilitating cellular senescence. ","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66338028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-01DOI: 10.12974/2312-5411.2015.02.01.3
Amy E Sobota, Emeka Umeh, Jennifer W Mack
Objective: This qualitative study sought to learn from young adults with sickle cell disease (SCD) about their experience leaving pediatric care and perspective on what makes a successful transition.
Methods: Fifteen young adults with SCD who had left pediatric care within the previous five years participated in focus groups led by a trained moderator. Transcripts were analyzed using grounded theory.
Results: Four main themes emerged from the analysis: facilitators of transition (meeting the adult provider prior to transfer, knowing what to expect, gradually taking over disease self-management and starting the process early), barriers to transition (negative perceived attitude of adult staff, lack of SCD specific knowledge by both patients and staff, and competing priorities interfering with transition preparation), what young adults wished for in a transition program (opportunities to meet more staff prior to transfer, more information about the differences between pediatric and adult care, learning from a peer who has been through the process, more SCD teaching, and flexibility in transition preparation) and how they define a successful transition (gradually assuming responsibility for self-management of their SCD).
Conclusion: Our findings present unique opportunities to learn from young adults with SCD about ways to improve current transition programs.
{"title":"Young Adult Perspectives on a Successful Transition from Pediatric to Adult Care in Sickle Cell Disease.","authors":"Amy E Sobota, Emeka Umeh, Jennifer W Mack","doi":"10.12974/2312-5411.2015.02.01.3","DOIUrl":"https://doi.org/10.12974/2312-5411.2015.02.01.3","url":null,"abstract":"<p><strong>Objective: </strong>This qualitative study sought to learn from young adults with sickle cell disease (SCD) about their experience leaving pediatric care and perspective on what makes a successful transition.</p><p><strong>Methods: </strong>Fifteen young adults with SCD who had left pediatric care within the previous five years participated in focus groups led by a trained moderator. Transcripts were analyzed using grounded theory.</p><p><strong>Results: </strong>Four main themes emerged from the analysis: facilitators of transition (meeting the adult provider prior to transfer, knowing what to expect, gradually taking over disease self-management and starting the process early), barriers to transition (negative perceived attitude of adult staff, lack of SCD specific knowledge by both patients and staff, and competing priorities interfering with transition preparation), what young adults wished for in a transition program (opportunities to meet more staff prior to transfer, more information about the differences between pediatric and adult care, learning from a peer who has been through the process, more SCD teaching, and flexibility in transition preparation) and how they define a successful transition (gradually assuming responsibility for self-management of their SCD).</p><p><strong>Conclusion: </strong>Our findings present unique opportunities to learn from young adults with SCD about ways to improve current transition programs.</p>","PeriodicalId":91541,"journal":{"name":"Journal of hematology research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/78/nihms756018.PMC4862600.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34544536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：